HUP0301691A3 - Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use - Google Patents
Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of useInfo
- Publication number
- HUP0301691A3 HUP0301691A3 HU0301691A HUP0301691A HUP0301691A3 HU P0301691 A3 HUP0301691 A3 HU P0301691A3 HU 0301691 A HU0301691 A HU 0301691A HU P0301691 A HUP0301691 A HU P0301691A HU P0301691 A3 HUP0301691 A3 HU P0301691A3
- Authority
- HU
- Hungary
- Prior art keywords
- tipe
- isoforms
- cloning
- expression
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19431800P | 2000-04-03 | 2000-04-03 | |
| US09/817,676 US6800470B2 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| PCT/US2001/009664 WO2001074837A1 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0301691A2 HUP0301691A2 (hu) | 2003-08-28 |
| HUP0301691A3 true HUP0301691A3 (en) | 2005-04-28 |
Family
ID=26889896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301691A HUP0301691A3 (en) | 2000-04-03 | 2001-03-26 | Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6800470B2 (https=) |
| JP (1) | JP4584525B2 (https=) |
| KR (1) | KR20020093017A (https=) |
| AU (1) | AU5100201A (https=) |
| CA (1) | CA2404965A1 (https=) |
| DK (1) | DK1268509T3 (https=) |
| HU (1) | HUP0301691A3 (https=) |
| MX (1) | MXPA02009781A (https=) |
| WO (1) | WO2001074837A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001074837A1 (en) * | 2000-04-03 | 2001-10-11 | Sankyo Company, Limited | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| AUPQ744700A0 (en) * | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
| US20030157082A1 (en) * | 2002-01-31 | 2003-08-21 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules |
| US20060205688A1 (en) * | 2002-10-14 | 2006-09-14 | Medvet Science Pty. Ltd. | Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase |
| WO2004061107A1 (ja) * | 2002-12-27 | 2004-07-22 | The New Industry Research Organization | スフィンゴシンキナーゼ2を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット |
| US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
| US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
| WO2018237379A2 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374616A (en) * | 1991-10-18 | 1994-12-20 | Georgetown University | Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor |
| WO1999061581A2 (en) * | 1998-05-26 | 1999-12-02 | Office Of The Dean Of Research And Graduate Education | Sphingosine kinase, cloning, expression and methods of use |
| EP1257637A2 (en) * | 2000-02-14 | 2002-11-20 | Curagen Corporation | Sphingosine kinases |
| WO2001074837A1 (en) * | 2000-04-03 | 2001-10-11 | Sankyo Company, Limited | Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
-
2001
- 2001-03-26 WO PCT/US2001/009664 patent/WO2001074837A1/en not_active Ceased
- 2001-03-26 HU HU0301691A patent/HUP0301691A3/hu unknown
- 2001-03-26 MX MXPA02009781A patent/MXPA02009781A/es unknown
- 2001-03-26 CA CA002404965A patent/CA2404965A1/en not_active Abandoned
- 2001-03-26 DK DK01924340.1T patent/DK1268509T3/da active
- 2001-03-26 US US09/817,676 patent/US6800470B2/en not_active Expired - Fee Related
- 2001-03-26 AU AU5100201A patent/AU5100201A/xx active Pending
- 2001-03-26 JP JP2001572526A patent/JP4584525B2/ja not_active Expired - Fee Related
- 2001-03-26 KR KR1020027013149A patent/KR20020093017A/ko not_active Withdrawn
-
2004
- 2004-04-22 US US10/830,677 patent/US7419814B2/en not_active Expired - Fee Related
-
2007
- 2007-08-14 US US11/891,964 patent/US7803595B2/en not_active Expired - Fee Related
-
2010
- 2010-07-27 US US12/804,664 patent/US8263349B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7419814B2 (en) | 2008-09-02 |
| US20040203104A1 (en) | 2004-10-14 |
| JP2004500117A (ja) | 2004-01-08 |
| US20020042101A1 (en) | 2002-04-11 |
| US6800470B2 (en) | 2004-10-05 |
| WO2001074837A1 (en) | 2001-10-11 |
| DK1268509T3 (da) | 2010-03-08 |
| CA2404965A1 (en) | 2001-10-11 |
| JP4584525B2 (ja) | 2010-11-24 |
| US20120107833A1 (en) | 2012-05-03 |
| US8263349B2 (en) | 2012-09-11 |
| KR20020093017A (ko) | 2002-12-12 |
| US7803595B2 (en) | 2010-09-28 |
| US20090169555A1 (en) | 2009-07-02 |
| AU5100201A (en) | 2001-10-15 |
| MXPA02009781A (es) | 2004-09-06 |
| HUP0301691A2 (hu) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL134013A (en) | Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors | |
| HUP0104496A3 (en) | Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions | |
| AU5752601A (en) | Splice-region antisense composition and method | |
| IL162328A0 (en) | Adjustable chair and method of use | |
| HUP9900163A3 (en) | Process for the preparation of sterol-and stanol-esters, and use thereof | |
| AU1194802A (en) | DNA expression vectors and methods of use | |
| AU7334901A (en) | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | |
| AU6838501A (en) | Enzyme-catalyzed polyamides and compositions and processes of preparing and using the same | |
| SI0736525T1 (en) | Benzonitriles as 5-HT agonists and antagonists | |
| IL151518A0 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase | |
| HUP0104550A3 (en) | Creamy laundry composition production and use thereof | |
| HUP0301691A3 (en) | Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use | |
| DK1138677T3 (da) | Fremgangsmåde til fremstilling af 11-amino-3-chlor-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepin og anvendelse til syntese af tianeptin | |
| IL144845A0 (en) | Vaccines and gene therapy compositions and methods of making and using the same | |
| HUP0203371A3 (en) | Adenosine receptor antagonists and methods of making and using the same | |
| ZA988921B (en) | 3,4-diarylthiazolin-2-one or -2-thione derivatives their methods of preparation and their uses in therapeutics | |
| PL352432A1 (en) | Neurothrophic pyrolydines and piperidines, their affinite composition and methods of using them | |
| HUP0103444A3 (en) | Composition for the protection of keratinous fibers containing ceramides and/or glycoceramides | |
| HUP0501056A2 (en) | Use of cationic surface active agents and fiber softening compositions containing the same | |
| PL360289A1 (en) | Arylpiperazine derivatives and their use as psychotropic agents | |
| PL351301A1 (en) | Novel inhibitors of metaloprotease, methods of obtaining them and pharmacological composition containing such inhibitors | |
| EP1352637A4 (en) | HAIRCARDANTS AND COMPOSITIONS COMPRISING THEM | |
| AU3281401A (en) | Antisense modulation of glycogen synthase kinase 3 alpha expression | |
| HUP0200162A3 (en) | Cloning and expression of haemophilus somnus transferrin-binding proteins | |
| HU0000039D0 (en) | Use of cationic monobenzene nitroanalines in the dyeing of keratinous fibres, dyeing composition and dyeing processes |